Why Retatrutide Got So Hard to Find

If you've looked for retatrutide lately, you've probably noticed sellers going quiet, websites disappearing and listings vanishing from social media. That's not a coincidence. In August 2026 the drug's developer and the FDA moved against the online market at the same time, and the pressure is landing less in courtrooms than on the payment and shipping systems sellers depend on.

What retatrutide is

Retatrutide is an investigational compound from Eli Lilly that acts on three hormone receptors (GLP-1, GIP and glucagon). It is still in Phase 3 clinical trials and is not approved anywhere in the world. Lilly has said it plans to submit it to the FDA in the first quarter of 2027, which puts any approval, at the earliest, in late 2027.

Lilly's six lawsuits

On August 12, 2026, Lilly filed six lawsuits against U.S. businesses it accuses of illegally selling retatrutide: Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide. The defendants include a compounding pharmacy, a medical spa and online sellers.

Lilly's central argument is that some sellers label retatrutide "for research use only" while actually marketing it for people to use, often with product sourced from unregulated overseas manufacturers. Alongside the lawsuits, Lilly said it has referred more than 200 people and businesses to the FDA, the Justice Department, state attorneys general and licensing boards, and has reported more than 14,000 websites, ads, social posts and listings in over 100 countries to the platforms hosting them.

Going after the plumbing

The part most buyers feel is not the lawsuits. When Lilly announced them, it also called on social media platforms, e-commerce services, payment processors, credit card companies, shipping carriers and customs agencies to help cut the trade off.

Payment access has always been the weak point for peptide sellers. PayPal and Square prohibit unlawful commerce, Wise lists peptides among transactions it doesn't support, and Stripe allows only research businesses with safeguards in place. Industry observers have noted that sellers who lose a payment processor tend to disappear within weeks, while sellers who keep one usually ride out regulatory pressure. With a drug maker of Lilly's size actively asking card networks and processors to act, that is the lever most likely to shrink the market.

In practice, that's why you see more crypto-only checkouts, sellers asking for payment apps or international transfers, and sites that are there one week and gone the next.

The FDA's warning letters

Twelve days later, on August 24, the FDA's drug center sent warning letters to five online peptide vendors, all centered on retatrutide. The agency said the products were unapproved new drugs, and its letters focused on websites that marketed them for people: dosing information, injection guidance and human-use claims. That is the line that matters. A research supplier sells to researchers, publishes a batch-specific Certificate of Analysis for every lot, and gives no dosing or human-use advice.

What it means if you're sourcing research compounds

Expect fewer, less stable sources. Sellers are leaving, changing names or moving to payment methods with fewer protections for the buyer.
Counterfeit risk goes up when supply shrinks. An independent, batch-specific Certificate of Analysis (identity by mass spectrometry, purity by HPLC) matters more than ever. A COA that can't be matched to the batch you received isn't proof of anything.
Retatrutide is not an approved medicine. Anyone interested in an approved GLP-1 treatment should talk to a licensed medical provider about the prescription options that exist today.

Sources

This article summarizes public reporting and court and regulatory actions. It is not legal or medical advice. Retatrutide is an investigational compound and is not approved for human use.

Research use only. This article summarizes laboratory and research-model information only. It is not medical advice and not guidance for human use. Products are not for human or animal consumption.